HealthDay News — Four in 10 plaque psoriasis patients achieve complete disease clearance with tapinarof cream, 1%, according to a study published online June 26 in the Journal of the American Academy of Dermatology.
Bruce Strober, M.D., Ph.D., from Yale University in New Haven, Connecticut, and colleagues assessed the long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof for the treatment of mild-to-severe plaque psoriasis. The analysis included 763 patients who completed the 12-week trial and were eligible for 40 weeks of open-label treatment and four weeks of follow-up.
The researchers found that 40.9% of patients achieved complete disease clearance (Physician Global Assessment [PGA] of 0). More than half of participants (58.2%) entering with PGA ≥2 achieved PGA of 0 or 1. For patients achieving PGA of 0, mean duration of remittive effect off-therapy was 130.1 days. No new safety signals were seen. Folliculitis (22.7%), contact dermatitis (5.5%), and upper respiratory tract infection (4.7%) were the most frequent adverse events.
“VTAMA [tapinarof] cream’s demonstrated combination of efficacy, remittive effect, durability, and tolerability make it a strong addition to the psoriasis armamentarium,” Philip M. Brown, M.D., J.D., chief medical officer of Dermavant Sciences, said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including Dermavant, which manufactures tapinarof and funded the study.